DelveInsight's "Psychosis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Psychosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers the emerging Psychosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Psychosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Psychosis: An Overview
Psychosis is characterized by an impaired association with reality. Psychosis is a symptom and not an illness. It is a symptom of serious mental disorders. A mental or physical illness, substance abuse, or extreme stress or trauma can cause it. Psychosis can also be a symptom of a mental illness, like schizophrenia or bipolar disorder. Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with Psychosis lose touch with reality. Two of the main symptoms are delusions and hallucinations.
Psychosis can affect people from all walks of life. Psychosis often begins when a person is in his or her late teens to mid-twenties. There are about 100,000 new cases of psychosis each year in the U.S. As many as 3 in 100 people will have an episode at some point in their lives.
Psychosis Market Key Facts
-
According to a research study by Gregory E Simon et al., incidence estimates would predict approximately 56,000 new cases per year among those aged 15–29 and an additional 58,000 among those aged 30–59.
-
People with severe mental illness (SMI), such as psychosis, are at increased risk of poor physical health and die on average 15 to 20 years earlier than the general population.
-
It was estimated that the cumulative incidence of psychotic symptoms in older adults has been found to be 6% with a follow-up duration of 3.6 years, 8% with a follow-up duration of 7 years, and 4.8% among 70-year-olds followed until death or age 90.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Psychosis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Psychosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Psychosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Psychosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Psychosis Epidemiology, Segmented as -
-
Total Prevalent Cases of Psychosis in the 7MM (2019–2032)
-
Diagnosed and Treatable Cases of Psychosis in the 7MM (2019–2032)
-
Age-specific Prevalent Cases of Psychosis in the 7MM (2019–2032)
-
Gender-specific Prevalent Cases of Psychosis in the 7MM (2019–2032)
Psychosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Psychosis market or expected to be launched during the study period. The analysis covers the Psychosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Psychosis market drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the Psychosis drugs based on their sale and market share.
The report also covers the Psychosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Psychosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/psychosis-market
Psychosis Companies Actively Working in the Therapeutics Market Include
-
Intra-Cellular Therapies
-
SAGE Therapeutics
-
Karuna Therapeutics
-
NeuroRx
-
Sunovion
And Many Others
Emerging and Marketed Psychosis Therapies Covered in the Report Include:
-
CAPLYTA : Intra-Cellular Therapies
-
Zuranolone: SAGE Therapeutics
-
KarXT: Karuna Therapeutics
-
Cycloserine/luras idone: NeuroRx
-
SEP-363856: Sunovion
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/psychosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Psychosis Competitive Intelligence Analysis
4. Psychosis Market Overview at a Glance
5. Psychosis Disease Background and Overview
6. Psychosis Patient Journey
7. Psychosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Psychosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Psychosis Unmet Needs
10. Key Endpoints of Psychosis Treatment
11. Psychosis Marketed Therapies
12. Psychosis Emerging Drugs and Latest Therapeutic Advances
13. Psychosis Seven Major Market Analysis
14. Attribute Analysis
15. Psychosis Market Outlook (In US, EU5, and Japan)
16. Psychosis Access and Reimbursement Overview
17. KOL Views on the Psychosis Market
18. Psychosis Market Drivers
19. Psychosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/psychosis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
"IgG4-Related Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the IgG4-Related Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the IgG4-Related Disease market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
